“童颜针年销3亿”背后：钱氏姐弟几乎掏空江苏吴中，股民追问“钱呢”！

Core Viewpoint - Jiangsu Wuzhong, a company involved in financial fraud, is facing delisting due to years of financial misconduct, with its stock price plummeting by 66.94% since entering the delisting period on December 9, 2025 [1][3]. Financial Fraud Details - Over the past four years, Jiangsu Wuzhong's chairman and vice-chairman, the Qian siblings, created a network of related transactions through at least six companies, resulting in a total revenue inflation of over 1.7 billion yuan and long-term fund occupation [3][4]. - The China Securities Regulatory Commission (CSRC) issued an administrative penalty against Jiangsu Wuzhong, revealing the siblings' illegal activities involving three subsidiaries and multiple related companies, which engaged in non-commercial trade to inflate revenue and profits [4][13]. Company Operations and Investigations - Investigations revealed that four out of five related companies had non-existent registered addresses, indicating potential fraudulent activities [4][11]. - Jiangsu Wuzhong's financial reports indicated significant non-operating fund occupation, with a total of 769 million yuan occupied by three companies, including Zhejiang Unode Trade Co., Ltd. [5][9]. Revenue Contributions from Related Parties - From 2020 to 2023, the inflated revenue from related parties was substantial, with contributions from the "related network" amounting to 4.85 billion yuan, 4.66 billion yuan, and 4.17 billion yuan in consecutive years [13][15]. - The top five customers of Jiangsu Wuzhong during this period were primarily linked to the aforementioned related companies, contributing significant revenue despite their questionable existence [12][17]. Management Response and Accountability - During a shareholder meeting, management failed to provide satisfactory answers regarding the missing funds, with the chairman emphasizing the legitimacy of trade operations despite evidence to the contrary [21][22]. - The CSRC's findings contradicted the management's claims, indicating that key executives were involved in the financial misconduct and had not conducted due diligence on the reported financials [22][26]. Future Outlook - Jiangsu Wuzhong's recent ventures into the medical aesthetics market, particularly the sales of a new product, have shown potential for revenue recovery, with sales reaching 326 million yuan in 2024 [23][24]. - However, the company's financial integrity remains in question, and the ongoing investigations may lead to further repercussions for the involved parties [26][27].